Cathie Wood, fund manager of Ark Invest, one of the most closely followed asset managers, often seizes the opportunity to lock in gains if one of her stocks surges. That’s exactly what she did this week.

An updated version of Exact Sciences' key product just got regulatory approval. That could help the healthcare stock stage a comeback.

Famed innovation investor Cathie Wood is attempting to stage a comeback after a somewhat sluggish past few years. Though the Ark funds may be down and trailing the market, Wood isn’t letting volatility stop her from continuing to make bold and,

Nubank, Latin America’s largest fintech bank, has the ability to grow globally. A recent pullback in its parent company’s shares offers an attractive entry point.

Cathie Wood, the CEO of Ark Invest, has several AI stocks in her investment management firm's actively managed ETFs. One of them is Recursion Pharmaceuticals ( RXRX -4.57%), a company looking to use AI to revolutionize the drug development process. Should investors follow Cathie Wood's lead?